The Result of Combined Modality Treatment for Non-Hodgkin's Lymphoma of Head and Neck

1985년 4월부터 1989년 9월까지 경부대학교병원 치료방사선과에서 두경부 악성 임파종으로 진단되어 복합화학요법 및 방사선 병용치료를 받은 26명을 대상으로 치료성적을 분석하였다. 완전관해율은 88%, 부분관해율은 12%였고 관해율에 영향을 미치는 예후인자는 없었다. 3년 생존율 및 3년무병 생존율은 각각 62.4% 및 65.2%였다. 생존율이 높았던 군은 편측성 임파절침범(p<0.05), 방사선량 5000cGy 이상(p<0.01), 화학요법 6회 이상(p=0.06)등이었다. 26예 중 8예(부분관해 3예 포함)에서 재발을 했으며 재발 양상은 국소재발 1예, 원격전이 1예, 인접조직에 대발 1예, 국소 재발 및 원격전이 2예 등이었다.

From April 1985 to September 1989, 26 patients with stage Ⅰ and Ⅱ non-Hodgkin's lymphoma of unfavorable histology localized in head and neck region were treated with combined modality(combination chemotherapy plus radiotherapy) at the Department of Therapeutic Radiology in Kyungpook National University Hospital. Of the 26 patients, 23 showed complete response and 3 partial response. Between these two groups there were no statistical differences according to the variables. Three-year survival and disease-free survival rate were 62.4% and 65.2%, respectively. Unilateral involvement of neck node (p<0.05), radiation dose over 5000 cGy (p<0.01), and 6 or more cycles chemotherapy (p=0.06) had a favorable effect on 3 yeat survival rate/ There were 8 recurrences including 3 partial responders, 1 local failure, 1 distant failure, 1 contiguous failure, and 2 simultaneous local and distant failure. It could be suggested that combined modality treatment might be necessary for treatment of stage Ⅰand Ⅱ Non-Hodgkin's lymphoma of unfavorable histology.